Academic Journal
Sustained Remission Without Corticosteroids among Patients with Pemphigus Who Had Rituximab as First-Line Therapy: Follow-Up of the Ritux 3 Trial
| العنوان: | Sustained Remission Without Corticosteroids among Patients with Pemphigus Who Had Rituximab as First-Line Therapy: Follow-Up of the Ritux 3 Trial |
|---|---|
| المؤلفون: | Tedbirt, Billal, Maho-Vaillant, Maud, Mignard, Claire, Golinski, Marie Laure, Calbo, Sébastien, Joly, Pascal, Hébert, Vivien, Houivet, Estelle, Prost-Squarcioni, Catherine, Caux, Frédéric, Alexandre, Marina, Musette, Philippe, Labeille, Bruno, Picard-Dahan, Catherine, Chaby, Guillaume, Richard, Marie Aleth, Tancrede-Bohin, Emmanuelle, Duvert-Lehembre, Sophie, Delaporte, Emmanuel, Bernard, Philippe, Ingen-Housz-Oro, Saskia, Vabres, Pierre, Quereux, Gaëlle, Dupuy, Alain, Debarbieux, Sébastien, Avenel-Audran, Martine, D Incan, Michel, Bédane, Christophe, Bénéton, Nathalie, Jullien, Denis, Dupin, Nicolas, Misery, Laurent, Machet, Laurent, Beylot-Barry, Marie, Dereure, Olivier, Sassolas, Bruno, Benichou, Jacques |
| المساهمون: | Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Aix Marseille Université (AMU), Assistance Publique - Hôpitaux de Marseille (APHM), Université de Lille, Université Paris Cité (UPCité), Université de Bordeaux (UB), Université de Montpellier (UM), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Université Paris-Saclay |
| المصدر: | ISSN: 2168-6068. |
| بيانات النشر: | CCSD American Medical Association |
| سنة النشر: | 2024 |
| مصطلحات موضوعية: | [SDV]Life Sciences [q-bio] |
| الوصف: | International audience ; © 2024 American Medical Association. All rights reserved.Importance: The Ritux 3 trial demonstrated the short-term efficacy and safety of first-line treatment with rituximab compared with a standard corticosteroid regimen in pemphigus. No data on the long-term follow-up of patients who received rituximab as first line are available. Objective: To assess the long-term efficacy and safety of the Ritux 3 treatment regimen. Design, Setting, and Participants: This 7-year follow-up study of the Ritux 3 trial included patients with pemphigus from 25 dermatology departments in France from January 1, 2010, to December 31, 2015. Exposure: Patients were initially randomized in the rituximab plus prednisone group or prednisone-alone group. Main outcomes and measures: The primary outcome was the 5- and 7-year disease-free survival (DFS) without corticosteroids, assessed by Kaplan-Meier curves. Secondary outcomes were occurrence of relapse, occurrence of severe adverse events (SAEs), and evolution of antidesmoglein (Dsg) antibody enzyme-linked immunosorbent assay values to predict long-term relapse. Results: Of the 90 patients in the Ritux 3 trial, 83 were evaluated at the end of follow-up study visit (44 in the rituximab plus prednisone group; 39 in the prednisone-alone group) with a median (IQR) follow-up of 87.3 (79.1-97.5) months. Forty-three patients (93%) from the rituximab plus prednisone and 17 patients (39%) from the prednisone-alone group had achieved complete remission without corticosteroids at any time during the follow-up. Patients from the rituximab group had much longer 5- and 7-year DFS without corticosteroids than patients from the prednisone-alone group (76.7% and 72.1% vs 35.3% and 35.3%, respectively; P <.001), and had about half the relapses (42.2% vs 83.7%; P <.001). Patients who received rituximab as second-line treatment had shorter DFS than patients treated as first line (P =.007). Fewer SAEs were reported in the rituximab plus prednisone group compared with the ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| Relation: | info:eu-repo/semantics/altIdentifier/pmid/38265821; PUBMED: 38265821 |
| DOI: | 10.1001/jamadermatol.2023.5679 |
| الاتاحة: | https://hal.science/hal-04616705 https://doi.org/10.1001/jamadermatol.2023.5679 |
| رقم الانضمام: | edsbas.DAB3B496 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1001/jamadermatol.2023.5679 |
|---|